Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers

NCT01129661 is registered in ClinicalTrials.gov with CSL Limited as lead sponsor.

NCT NCT01129661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers
Lead sponsor
CSL Limited
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2010
Completion date
January 31, 2011
Enrollment
57 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy